For inflammatory bowel disease, mesalamine, corticosteroids, immunomodulators (azathioprine, methotrexate), and biologics (infliximab, adalimumab, vedolizumab, ustekinumab) all have Level 1 evidence from Phase III trials with thousands of patients
Mechanistically, studies suggest vascular and tendon/muscle healing effects
Tirzepatide Once Weekly for the Treatment of Obesity: Participants in this study complete a 60-week Weight-Loss Period on Tirzepatide, followed by a 52-week Weight Maintenance Period, where they are assigned to either Tirzepatide 5 mg, the maximum tolerated dose of Tirzepatide, and saw successful results
Dose-response relationships and timing considerations Optimal outcomes require proper dosing and timing strategies